# Scoping

|  |  |
| --- | --- |
| **Details of suggested modular update** | |
| **Modular update title** | EQ-5D-5L value set |
| **Summary of suggested modular update** | This update to NICE’s methods will recommend that the new EQ-5D-5L value set is used for reference-case analyses in economic evaluations. |
| **Will documents other than NICE manuals be created or updated? If yes, please describe** | It is anticipated that a supplementary document with guidance on mapping data onto the EQ-5D-5L value set will be created as part of the update. |
| **Scope of modular update** | |
| **Areas that will be covered** | This update will be relevant to health technology evaluations and guidelines.  Before NICE consults on the adoption of the new EQ-5D-5L value set into our methods, we will:   * Review the results of an impact assessment analysing whether incremental cost-effectiveness ratios (ICERs) are sensitive to using the EQ-5D-5L value set instead of the EQ-5D-3L value set, using 37 published NICE Technology Appraisals as case studies. This will be an educational exercise and not influence the decision on whether or not to adopt the EQ-5D-5L value set. The impact assessment will be completed by the National Institute for Health Research (NIHR) Policy Research Unit in Economic Methods of Evaluation of Health and Care Interventions (EEPRU). The impact assessment will be finalised and published once the value set has undergone peer review as part of the journal publication process (at time of issuing this scope (September 2025), the value set publication is in preparation). * Develop guidance on mapping onto the  EQ-5D-5L value set. * Conduct an equalities and health inequalities impact assessment. |
| **Areas that will not be covered** | No further quality assurance of the value set will be conducted (with the exception of the journal peer review process). We have had sufficient evidence of robust quality assurance throughout the study (summarised in the [study governance document](https://euroqol.org/wp-content/uploads/2023/12/New-UK-EQ-5D-5L-valuation-study-Governance-v1-06FEB2020-1.pdf)), as well as consensus from the study’s steering group that the data are high quality and the modelling approach is appropriate and well-justified.  We recognise that cost-effectiveness results may be sensitive to using the EQ-5D-5L value set instead of the EQ-5D-3L value set (pending the results of EEPRU’s impact assessment). The introduction of the EQ-5D-5L value set will not trigger:   * Automatic reviews of existing NICE recommendations that were assessed using the EQ-5D-3L value set. * Review of our standard cost-effectiveness thresholds, which are set to remain at £20,000–£30,000 per quality-adjusted life year (QALY) for the duration of the [2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG)](https://www.gov.uk/government/publications/2024-voluntary-scheme-for-branded-medicines-pricing-access-and-growth). |